BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9432685)

  • 1. ASO Author Reflections: Upfront Surgery Followed by Adjuvant Therapy: An Option for IIIA-N2 Non-small Cell Lung Cancer.
    Fu F; Zhang Y; Chen H
    Ann Surg Oncol; 2023 Dec; 30(13):8284. PubMed ID: 37755561
    [No Abstract]   [Full Text] [Related]  

  • 2. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors and therapeutic strategy in non-small-cell bronchial carcinoma].
    Wolf M
    Praxis (Bern 1994); 1997 Oct; 86(42):1640-6. PubMed ID: 9432685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bronchial cancer--development, diagnosis, therapy, prognosis].
    Zöchbauer S; Krajnik G; Huber H
    Wien Klin Wochenschr; 1994; 106(14):431-47. PubMed ID: 7941590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant chemotherapy and chemoradiotherapy in locally advanced stage IIIA and IIIB of non-small-cell bronchial carcinoma (the Essen concept)].
    Eberhardt W
    Praxis (Bern 1994); 1997 Oct; 86(42):1647-53. PubMed ID: 9432686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [With reference to later intra-/extrathoracic recurrence manifestations also after so-called radical operation: when are (neo-)adjuvant measures indicated?].
    Drings P
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():805-9. PubMed ID: 9101994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined-modality therapy for lung cancer].
    Miura S; Yamamoto N
    Nihon Rinsho; 2010 Jun; 68(6):1121-8. PubMed ID: 20535966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?
    Van Meerbeeck JP; De Pauw R; Tournoy K
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):199-206. PubMed ID: 18279061
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.